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Abstract
CYP1A1 is the phase I enzyme that detoxifies the carcinogen or converts it into a more electrophilic form, metabo-
lized by phase II enzymes like GSTP1. These detoxifying genes have been extensively studied in association with
head and neck cancer (HNC) in different ethnic groups worldwide. The current study was aimed at screening genetic
polymorphisms of genes CYP1A1 and GSTP1 in 388 Pakistani HNC patients and 150 cancer-free healthy controls,
using PCR-SSCP. No already known variants of either gene were found, however a novel frameshift mutation due to
insertion of T (g.2842_2843insT) was observed in the CYP1A1 gene. A statistically significant number (5.4%) of
HNC cases, with the mean age of 51.75 (15.7) years, presented this frameshift mutation in the conserved domain of
CYP1A1. Another novel substitution mutation in was found in the GSTP1 gene, presenting TA instead of AG. The
g.2848A > T polymorphism causes a leucine-to-leucine formation, whereas g.2849G > A causes alanine-to-
threonineformationataminoacidpositions166and167,respectively.Theseexonicmutationswerefoundin9.5%of
the HNC patients and in none of the controls. In addition, two intronic deletions of C (g.1074delC and g.1466delC)
were also found in 11 patients with a mean age of 46.2 (15.6) years. In conclusion, accumulation of mutations in
genes CYP1A1 and GSTP1 appears to be associated with increased risk of developing HNC, suggesting that muta-
tions in these genes may play a role in the etiology of head and neck cancer.
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Introduction
Head and neck cancer (HNC) includes carcinomas of
the oral cavity, pharynx, and larynx. It is the sixth most fre-
quent cancer worldwide (Devasena et al., 2007), amount-
ing to half a million diagnosed cases every year (Faheem,
2007). HNC represents 40.1% of all cancers registered
(Parkin et al., 1993) and is the second most prevalent in the
Pakistani population (Hanif et al., 2009).
Many environmental factors, including smoking and
alcoholconsumption,aswellasgeneticfactors,arerespon-
sible for the development of HNC. Tobacco addiction is an
important and strong risk factor associated with HNC (Ra-
janietal.,2003),howeverthemajorityoftobacco-addicted
individuals do not develop this type of cancer (Lewin et al.,
1998). The reason for this contrast is probably the fact that
bothexogenousexposureandgeneticpredispositionarein-
volved in the development of HNC (Peters et al., 2006;
Devasena et al., 2007).
Polymorphisms in the carcinogen-detoxifying genes
may increase or decrease carcinogen activation or detoxifi-
cation,withaconsequentvariationincancerrisk(Curranet
al., 2000; Devasena et al., 2007). Most of the carcinogenic
moieties are metabolically processed by xenobiotic-meta-
bolizing enzymes in two broad steps: phase I, mediated by
cytochrome p450s (CYPs), and phase II, catalyzed by glu-
tathione S-transferases (GSTs). Phase I reactions expose
functional groups of the substrates and therefore yield
highlyreactiveintermediates.Theseintermediatesformthe
substratesforphaseIIreactions,whichinvolvestheirelimi-
nation.Hence,thecoordinatedexpressionandregulationof
phase I and II enzymes determine the outcome of carcino-
gen exposure. Sequence variations or polymorphisms in
these genes can alter the expression, function and activity
of these enzymes and, consequently, the cancer risks (Duk
et al., 2004).
Cytochromes P-450 (phase I enzyme) that are known
to exhibit polymorphism include CYP1A1, CYP1B1
(Crofts et al., 1993; Bartsch et al., 2000), CYP2A6,
CYP2C9, CYP2C19, CYP2D6 and CYP2E1 (Bartsch et
al., 2000). Polymorphism of the CYP1A1 gene has been
studied most extensively in relation to HNC (Toru et al.,
2008). It is located on chromosome 15q22-24 and encodes
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Research Articlean aromatic hydrocarbon hydroxylase that converts PAHs
to carcinogen and is predominantly expressed in extra-
hepatic tissues (Crofts et al., 1993). Its polymorphisms
have been shown to increase the microsomal catalytic ac-
tivityforactivatingpro-carcinogens(Cascorbietal.,1996).
GSTP1islocatedonchromosome11q13andencodes
one of the phase II detoxifying enzymes. GSTP1 catalyse
the conjugation of glutathione (GSH) to toxic compounds,
resulting in more water-soluble and less biologically active
products that are easily excreted. To date, two polymorphic
alleles are known for GSTP1, GSTP1*B and GSTP1*C, in
addition to the wild-type allele, GSTP*A (Ali et al., 1997).
Both alleles present an A-to-G transition at nucleotide 313
(codon 104), causing an isoleucine-to-valine change. The
GSTP1*C allele presents a C-to-T transition at nucleotide
341 (codon 113), in addition to the substitution at nucleo-
tide 313, that changes alanine to valine. These two GSTP1
proteins differ in specific activity, affinity for electrophilic
substrates and heat stability (Ali et al., 1997 Zimniak et al.,
1994).
These gene polymorphisms show different trends in
different ethnic groups and have been found to be common
in South East Asia (Rajani et al., 2003; Devasena et al.,
2007). The current study was designed to search for
CYP1A1 and GSTP1gene polymorphisms in a Pakistani
sample.
Material and Methods
The present case-control study consisted of 388 cases
with pathologically confirmed head and neck cancer and
150 cancer-free healthy individuals, matched for age and
gender, as controls. They were all recruited from the Na-
tionalOncologyandRadiotherapyInstitute(NORI)andthe
Institute of Medical Sciences (PIMS), Pakistan, from
March 2008 to September 2009, with prior approval from
the Ethics Committees of both the CIIT and the hospitals.
Allstudysubjectsparticipatedonavolunteerbasis,within-
formed consent. All subjects were personally interviewed
according to a structured questionnaire.
Blood from the subjects was sampled before starting
therapy. Blood samples were collected in EDTA-con-
tainingtubesandstoredat20°Cuntilfurtheruse.DNAwas
isolated using an organic protocol with phenol-chloroform
extraction, as previously described (Baumgartner-Parzer et
al., 2001; Vierhapper et al., 2004). The isolated DNA was
electrophoresed on 1% ethidium-bromide-stained agarose
gel, and photographed (BioDocAnalyze Biometra). Dilu-
tions of 5 ng were made of each isolated DNA and stored at
4 °C until further use.
Primers for all exons of CYP1A1 and GSTP1 were
synthesized by using the primer 3 input software version
0.4.0 and BLAST using NCBI PRIMER BLAST (Table 1).
2 L of DNA (10 ng/L) were added to a 20 L PCR reac-
tion mixture composed of 2 L PCR buffer, 2 L of each
primer (10 mM), 0.24 L deoxynucleotide triphosphate
(25 mM) and 0.2 L Taq polymerase (5u/L). The reaction
mixture was then placed in a 9700 ABI Systems thermal
cyclerfor5minat94°Candsubjectedto30cyclesat94°C
for 25 s, annealing temperature for 1 min, and 72 °C for
1min,followedbyafinalstepat72°Cfor10min,andheld
at 4 °C. In order to avoid any false-positive alteration, a
proofreading polymerase reaction was also performed in
this regard.
Amplification products were resolved on 2% ethi-
dium bromide-stained agarose gel, along with a 100 bp
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Table 1 - Primer sequences used in PCR SSCP for GSTP1 and CYP1A1.
Exons Primer Sequences (5’-3’) Product
size (bp)
Exon1F GGTTGTGATTAGTTCTTTGG 459
Exon1R GTGTTGAAAAGGAGAGGAGT
Exon2aF GAATGAAATGGAGTTGGATT 381
Exon2aR AGGATCGTATTCTCTGCTGT
Exon2bF AGAACCAAGGCTCCATAAT 476
Exon2bR ATTGCATGAATGTGGTTAGA
CYP1A1
gene
Exon3F CCTTCTCTCCATTCCCCTGT 150
Exon3R GTAAGACAAAGGCTGGTGCTG
Exon4F GCCTGGGTTAAGTATGCAGAT 154
Exon4R CTGACAGGGCACCCAATACT
Exon5F TGACACTTTGAATGCTCTTTCC 154
Exon5R AAACCAAACCCATGCAAAAG
Exon6F AGGACCCTGGAGTCGATTG 163
Exon6R AGCTCCTGGCACTGGTAGAG
Exon 7aF GCATTGATCCTCCTGTCCAT 594
Exon 7aR CAGAGGCAAGTCCAGGGTAG
Exon 7bF TGTCTACCTGGTCTGGTTGG 600
Exon 7bR CCTCCAGGACAGCAATAAGG
Exon 7cF CTGCCAAGAGTGAAGGGAAG 590
Exon 7cR AACACAGAATGGGGTTCAGG
Exon1F AGTTCGCTGCGCACACTT 465
Exon1R GACGTCCTGGGTCCCCTA
Exon2F GTCCCCAGTGCCGTTAGC 277
Exon2R GATAAGGGGGTTCGGATCTC
Exon3F GGAGGAACCTGTTTCCCTGT 277
Exon3R GTCCCCCGATCCTAGTCAC
GSTP1
gene
Exon4F GGGGCTGTGACTAGGATCG 237
Exon4R GGGCAGCTGATTTAAACAAAA
Exon5F ACAGACAGCCCCCTGGTT 227
Exon5R AAGCCACCTGAGGGGTAAG
Exon6F GCAAGCAGAGGAGAATCTGG 278
Exon6R GCTAAACAAATGGCTCACACC
Exon7F AGACCTAGGGGATGGGCTTA 451
Exon7R GTGCTGGAGGAGCTGTTTTCDNAladder.Allgelelectrophoresisphotographswereana-
lyzedbytwotechniciansblindtoeachother’sassessments.
ThePCRproductwassubmittedtosingle-strandcon-
formational polymorphism (SSCP) analysis, according to
the procedure described by Telenti et al. (1993) and Sheen
etal.(2009).Afterethidiumbromidestaining,theSSCPre-
sults were analyzed with a gel documentation system
(BioDocAnalyze Biometra) and photographed. The sam-
ples showing mobility shifts were sequenced.
Forty-eight samples were screened based on SSCP
analysis and sequenced by Macrogen (Korea) using for-
ward and reverse primers. The reverse-primer-sequenced
results were made forward-complementary and analyzed
using BioEdit v 7.0.5 software. The reference sequences
for CYP1A1 (MIM ID-108330 and NG_008431.1) and
GSTP1 (MIM ID-134660 and NG_012075.1) were ob-
tained from NCBI. Statistical analysis was performed by
using the SPSS statistics 17.0 software and GraphPad
Prism 5 Demo for calculating odd ratios, with a 95% con-
fidence interval.
Results
No previously reported polymorphisms of the
CYP1A1 gene were found in the present study. Instead, a
novel frameshift mutation due to thymidine insertion
(g.2842_2843insT) was found (Figure 1). A significant
number of patients had a mutation in exon 2 of the CYP1A1
gene, not observed in any of the controls. Due to this muta-
tion, the conserved core structure was altered, which dis-
turbs the proper folding and heme-binding ability of the
cytochrome P450 molecules. This frameshift mutation
causesachangeinthesubsequent495nucleotidesequence,
altering the protein structure of the CYP1A1 gene. The
mean age of patients showing the frameshift mutation was
51.75 (15.7) years and 62% were males (Table 2).
Thirty-seven SSCP variants for GSTP1 exon 7 were
sequenced (Figure 2). A significant number (p < 0.001) of
patients had substitution mutations of g.2848A>Ta n d
g.2849G > A in exon 7 of the GSTP1 gene (Figure 3). The
g.2848A > T mutation causes a sense mutation, changing
the amino acid coding sequence from CUU to CUA at
codon 166. Both the amino acid sequences CUU and CUA
code for leucine. However, at codon 167, g.2849G > A
causes a missense mutation, resulting in the change of the
amino-acid-coding sequence from GCC to ACC. GCC
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Figure 1 - Position of T insertion at nucleotide 2842 in CYP1A1 exon 2,
causing a frameshift mutation, in HNC patients.
Figure 2 - Substitution mutations of A to T and G to A at positions 2848
and 2849 of the GSTP1 gene, respectively, in HNC patients.
Figure 3 - Sequencing results showing deletion of C between C and A in
intron 3 at position 1074 (a) and deletion of C in intron 4 of the GSTP1
gene (b) in HNC patients.codes for alanine, while ACC codes for threonine. These
substitution mutations are located in the C-terminal region
oftheGSTP1gene.Thesemutationswereobservedinasta-
tistically significant (OR 2.08, 95% CI 0.97-4.45) number
of male patients. Cancer of the oral cavity was found to be
the most prevalent (p < 0.05, OR 3.4, 95% CI 1.3-8.8) in
these patients (Table 2). These mutations were not ob-
served in any of the healthy controls.
The results of exon 4 and 5 sequencing, along with
intron-exon junctions, showed cytosine deletions. These
deletionswerelocatedinintrons3and4,andwerefoundin
2.08% of the patients (Figure 3). Intronic deletions
(g.1074delC and g.1466delC) were found in a statistically
significant (p < 0.05) number of patients and in none of the
controls. The mean age of patients showing these deletions
was 48.18 ( 11.8) years, and a significant (p < 0.05, OR
4.5, 95% CI 0.94-21.53) number of patients were male and
had cancer of the oral cavity (OR 20.25, 95% CI 2.32-
176.8) (Table 2).
Discussion
In an earlier study, 13 nucleotide polymorphisms (at
12 positions: 3229, 3219, 134, 1636, 2414, 2453, 2455,
2461, 2500, 2546, 3205, and 3801) and one frameshift mu-
tationduetoasingle-baseinsertionbetween2346and2347
in CYP1A1 have been reported in the Korean population
(Duketal.,2004).Amongthese,ninepolymorphismswere
associatedwithaminoacidsubstitutions(Spurretal.,1987;
Hayashi et al., 1991; Crofts et al.; 1993; Cascorbi et al.,
1996;SmartandDaly,2000;Chevalieretal.,2001;Saitoet
al., 2002). Insertion mutations of 33 nucleotide sequences
causing frameshift mutations in CYP1A1 have also been
found (Xiang et al., 2001). The population frequencies of
the various CYP1A1 polymorphisms follow diverse ethnic
and/or geographic patterns (Garte et al., 2001).
In the present study, none of the so far reported vari-
ants of the CYP1A1 gene were observed in the Pakistani
population. Instead, a novel frameshift mutation
(g.2842_2843insT) affecting 495 nucleotide sequences
was observed in the studied patients. Due to this mutation,
all the amino acids subsequent to the insertion were
changed and the protein structure was altered, leading to an
altered protein expression.
Similar to CYP1A1, no previously reported variants
were found for the GSTP1 gene. These results are different
from most of the studies in the literature (Curran et al.,
2000; Cho et al.; 2006; Peters et al., 2006). A possible rea-
son for this may be the variation in GSTP1 polymorphisms
indifferentpopulations.Moyeretal.(2008)found35SNPs
in four ethnic groups in America, and 17 of these SNPs
were novel mutations.
Thisstudyisthefirsttoreportfournovelmutationsin
theGSTP1geneinthePakistanipopulation.Twosilentmu-
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Table 2 - Statistical evaluation of frameshift mutation in gene CYP1A1 and exonic and intronic mutations in gene GSTP1 in HNC patients
CYP1A1 mutation GSTP1 substitution mutation GSTP1 intronic variation
Variables Frame-shift OR (CI 95%) A>Ta n dG>A O R( C I95%) at 1074 OR (CI 95%)
Total of patients 21 9.4 (1.3-70.8) 9.50% 15.7 (2.14-115.5) 2.80% 4.3 (0.56-34)
Gender
Female 62% 1.6 (0.09-29.8) 32.40% 0.48 (0.22-1.03) 18.20% 0.22 (0.22-1.03)
Male 38% 0.6 (0.03-11.3) 67.60% 2.08 (0.97-4.45) 81.80% 4.5 (0.94-21.53)
Age (years)
Mean 51.75  15.7 46.2  15.6 48.18  11.8
< 48 52% 1.1 (0.06-20.0) 45.90% 0.85 (0.41-1.75) 45.50% 0.83 (0.424-2.85)
> 48 48% 0.9 (0.05-16.5) 54.10% 1.17 (0.57-2.42) 54.50% 1.2 (0.35-4.1)
Smoking
Yes 62% 1.6 (0.09-29.8) 64.90% 1.85 (0.87-3.89) 63.60% 1.75 (0.49-6.22)
No 38% 0.6 (0.03-11.3) 35.10% 0.54 (0.26-1.14) 36.40% 0.57 (0.16-2.03)
Occupation
Job 9 0.75 (0.04-13.7) 35.10% 0.3 (0.13-0.76) 45.50% 0.69 (0.13-3.72)
Jobless 8 0.62 (0.03-11.3) 35.10% 0.3 (0.13-0.76) 18.20% 0.05 (0.006-0.43)
House- wife 4 0.2 (0.01-4.62) 29.80% 0.18 (0.07-0.49) 36.30% 0.33 (0.06-1.86)
Location of Cancer
Oral cavity 76% 3.2 (0.17-61.02) 64.90% 3.4 (1.3-8.8) 81.80% 20.25 (2.32-176.8)
Pharynx 14% 0.17 (0.01-3.4) 18.90% 0.05 (0.02-0.2) 9.10% 0.01 (0.0005-0.18)
Larynx 10% 0.11 (0.005-2.4) 16.20% 0.03 (0.02-0.13) 9.10% 0.01 (0.0005-0.18)tations with intronic deletions of C, one exonic non-
synonymous and one synonymous substitution mutations
altering GSTP1 mRNA expression were found. The exonic
substitutions result in leucine-to-leucine formation and a
nonsynonymous alanine-to-threonine. These two exonic
mutations are located at codon 166 and 167, and they are in
the GST motif II ( 6 helix residues 150-167 and the pre-
ceding loop residues 137-149). GST motif II contains the
“hydrophobic staple” made up of Ile149 and Tyr154, nec-
essary for GST folding (Dragani et al., 1997); mutations in
this motif have been shown to affect folding and refolding
pathways of the enzymes (Dragani et al., 1997; Cocco et
al., 2001 Rossjohn et al., 2000; Stenberg et al., 2000). It is
hypothesizedthattheGST motifII isinvolvedinthenucle-
ation mechanism of the protein and that the substitution of
alanine by threonine may alter this transient substructure.
The current mutation causes a change in the C-terminal
protein domain, altering the functional activity of GSTP1.
Mechanistically, two single nucleotide polymorphisms in
the intronic region of the GSTP1 gene may either result in
differential binding of putative regulatory proteins, or it
may be in linkage disequilibrium with other mutations af-
fecting GSTP1 inducibility.
In conclusion, mutations in genes CYP1A1 and
GSTP1 were found to be significantly higher in Pakistani
patientswithHNCcomparedtohealthycontrols.However,
to determine the role of these genetic changes in increasing
the cancer risk, an integrated analysis of many genes in-
volved in cancer development is required. The identifica-
tion of mutations in genes associated with the xenobiotic
metabolism may provide a basis for understanding the high
degree of individual variability in the susceptibility to the
adverse effects of environmentalsubstances.
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